IGMS RSI Chart
Last 7 days
30.3%
Last 30 days
1.2%
Last 90 days
-11.8%
Trailing 12 Months
-13.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 1.6M | 1.7M | 1.9M | 2.1M |
2022 | 0 | 0 | 0 | 1.1M |
2021 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 29, 2024 | behrens m kathleen | acquired | - | - | 3,078 | - |
Mar 29, 2024 | lee michael stewart | acquired | - | - | 1,734 | - |
Mar 29, 2024 | thompson elizabeth h.z. | acquired | - | - | 1,452 | - |
Mar 29, 2024 | redmile group, llc | acquired | - | - | 1,734 | - |
Mar 29, 2024 | topsoe jakob haldor | acquired | - | - | 1,734 | - |
Mar 29, 2024 | baker bros. advisors lp | acquired | - | - | 3,988 | - |
Mar 29, 2024 | topsoe christina teng | acquired | - | - | 2,687 | - |
Mar 28, 2024 | redmile group, llc | sold | - | - | -12,464 | - |
Mar 28, 2024 | baker bros. advisors lp | bought | 937,632 | 9.6194 | 97,473 | - |
Mar 27, 2024 | baker bros. advisors lp | bought | 257,170 | 9.2361 | 27,844 | - |
Which funds bought or sold IGMS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | SIMPLEX TRADING, LLC | sold off | -100 | -15,000 | - | -% |
Apr 25, 2024 | Bank of New York Mellon Corp | reduced | -4.7 | 46,091 | 478,186 | -% |
Apr 25, 2024 | nVerses Capital, LLC | new | - | 15,440 | 15,440 | 0.04% |
Apr 23, 2024 | AMALGAMATED BANK | reduced | -64.51 | -5,000 | 3,000 | -% |
Apr 15, 2024 | EXCHANGE TRADED CONCEPTS, LLC | added | 46.66 | 111,284 | 269,573 | 0.01% |
Apr 05, 2024 | NBC SECURITIES, INC. | unchanged | - | - | 1,000 | -% |
Apr 05, 2024 | CWM, LLC | new | - | - | - | -% |
Apr 05, 2024 | GAMMA Investing LLC | new | - | 733 | 733 | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 58.00 | 58.00 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -0.32 | -59,750 | 7,455,310 | -% |
Unveiling IGM Biosciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to IGM Biosciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.4B | 2.5B | 74.73 | 6.21 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.37 | 15.16 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
IGM Biosciences Inc News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q4 |
Revenue | 27.9% | 651,000 | 509,000 | 448,000 | 522,000 | 372,000 | 331,000 | 366,000 | - |
Operating Expenses | -2.2% | 65,770,000 | 67,269,000 | 68,656,000 | 63,896,000 | 56,636,000 | 60,843,000 | 59,590,000 | 50,680,000 |
S&GA Expenses | -7.4% | 11,580,000 | 12,507,000 | 12,983,000 | 13,002,000 | 11,619,000 | 12,664,000 | 12,372,000 | 11,511,000 |
R&D Expenses | -1.0% | 54,190,000 | 54,762,000 | 55,673,000 | 50,894,000 | 45,017,000 | 48,179,000 | 47,218,000 | 39,169,000 |
EBITDA Margin | 10.2% | -111 | -124 | -135 | -139 | -201 | - | - | - |
Income Taxes | 0.8% | 242,000 | 240,000 | 109,000 | 87,000 | - | - | - | - |
Earnings Before Taxes | 2.1% | -60,453,000 | -61,749,000 | -64,314,000 | -59,222,000 | -52,576,000 | -58,037,000 | -58,595,000 | - |
EBT Margin | 10.2% | -115 | -128 | -139 | -143 | -206 | - | - | - |
Net Income | 2.1% | -60,695,000 | -61,989,000 | -64,423,000 | -59,309,000 | -52,576,000 | -58,037,000 | -58,595,000 | -50,642,000 |
Net Income Margin | 10.1% | -115 | -128 | -140 | -143 | -206 | - | - | - |
Free Cashflow | -14.5% | -49,456,000 | -43,204,000 | -57,018,000 | -54,934,000 | -40,553,000 | -43,124,000 | 109,484,000 | -37,063,000 |
Balance Sheet | ||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Assets | -10.7% | 423 | 474 | 481 | 463 | 513 | 541 | 582 | 258 | 298 | 332 | 351 | 380 | 409 | 212 | 229 | 243 | 261 | 270 | - |
Current Assets | -12.8% | 348 | 398 | 402 | 385 | 438 | 480 | 522 | 198 | 241 | 268 | 290 | 341 | 373 | 185 | 201 | 213 | 231 | 248 | 2.00 |
Cash Equivalents | -35.6% | 113 | 175 | 151 | 140 | 121 | 177 | 221 | 75.00 | 133 | 166 | 246 | 252 | 241 | 27.00 | 32.00 | 48.00 | 36.00 | 194 | 2.00 |
Net PPE | 3.7% | 38.00 | 37.00 | 38.00 | 37.00 | 33.00 | 32.00 | 31.00 | 30.00 | 28.00 | 28.00 | 27.00 | 26.00 | 23.00 | 14.00 | 10.00 | 5.00 | 4.00 | 3.00 | 1.00 |
Liabilities | -0.1% | 220 | 220 | 222 | 223 | 226 | 213 | 207 | 53.00 | 53.00 | 47.00 | 28.00 | 25.00 | 27.00 | 24.00 | 22.00 | 19.00 | 21.00 | 15.00 | 9.00 |
Current Liabilities | -1.1% | 42.00 | 43.00 | 44.00 | 44.00 | 45.00 | 44.00 | 36.00 | 27.00 | 28.00 | 20.00 | 19.00 | 15.00 | 17.00 | 13.00 | 11.00 | 8.00 | 9.00 | 6.00 | 9.00 |
Shareholder's Equity | -19.9% | 203 | 254 | 259 | 239 | 287 | 328 | 375 | 205 | 245 | 286 | 322 | 356 | 382 | 188 | 207 | 224 | 240 | 255 | - |
Retained Earnings | -8.0% | -821 | -760 | -698 | -634 | -574 | -522 | -464 | -405 | -353 | -303 | -258 | -220 | -188 | -163 | -143 | -124 | -107 | -92.39 | -64.07 |
Additional Paid-In Capital | 1.0% | 1,024 | 1,014 | 957 | 873 | 862 | 851 | 840 | 610 | 598 | 588 | 581 | 575 | 570 | 352 | 350 | 348 | 347 | 347 | 1.00 |
Shares Outstanding | 5.1% | 52.00 | 50.00 | 45.00 | 44.00 | 42.00 | 44.00 | 44.00 | 34.00 | 33.00 | 33.00 | 33.00 | 33.00 | 31.00 | 31.00 | 31.00 | 30.00 | 9.00 | 4.00 | 0.00 |
Float | - | - | - | 132 | - | - | - | 219 | - | - | - | 664 | - | - | - | 514 | - | 265 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -19.7% | -48,008 | -40,121 | -53,105 | -50,997 | -37,858 | -40,413 | 111,307 | -38,889 | -35,300 | -34,406 | -27,014 | -28,262 | -23,342 | -15,075 | -13,077 | -16,387 | -12,067 | -15,380 | -9,324 | -8,345 | - |
Share Based Compensation | -22.7% | 9,237 | 11,954 | 14,309 | 11,047 | 11,109 | 10,816 | 11,286 | 11,499 | 8,548 | 6,212 | 5,609 | 5,504 | 2,582 | 2,594 | 1,955 | 1,323 | 400 | 334 | 141 | 139 | - |
Cashflow From Investing | -175.2% | -14,693 | 19,549 | -6,325 | 69,824 | -18,811 | -3,748 | -183,982 | -19,103 | 2,240 | -47,110 | 20,720 | 39,611 | 21,228 | 11,485 | -2,953 | 28,529 | -143,727 | -58,363 | -433 | -715 | - |
Cashflow From Financing | -99.1% | 402 | 44,639 | 69,952 | 75.00 | 482 | 297 | 218,531 | 72.00 | 1,491 | 1,071 | -33.00 | -53.00 | 215,910 | -917 | -234 | 22.00 | -1,994 | 224,650 | 49,569 | 10,033 | - |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Collaboration revenue | $ 2,130 | $ 1,069 | $ 0 |
Operating expenses: | |||
Research and development | 215,519 | 179,289 | 127,026 |
General and administrative | 50,072 | 49,736 | 38,297 |
Total operating expenses | 265,591 | 229,025 | 165,323 |
Loss from operations | (263,461) | (227,956) | (165,323) |
Other income (expense) | |||
Interest income | 17,743 | 7,035 | 159 |
Other expense | (20) | (181) | 0 |
Total other income (expense) | 17,723 | 6,854 | 159 |
Loss before income tax expense | (245,738) | (221,102) | (165,164) |
Income tax expense | (678) | 0 | 0 |
Net loss | $ (246,416) | $ (221,102) | $ (165,164) |
Net loss per share, basic | $ (4.71) | $ (5.32) | $ (4.93) |
Net loss per share, diluted | $ (4.71) | $ (5.32) | $ (4.93) |
Weighted-average common shares outstanding, basic | 52,311,958 | 41,543,954 | 33,479,782 |
Weighted-average common shares outstanding, diluted | 52,311,958 | 41,543,954 | 33,479,782 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 112,520 | $ 121,231 |
Restricted cash | 592 | 689 |
Marketable securities | 225,157 | 305,931 |
Prepaid expenses and other current assets | 9,328 | 10,570 |
Total current assets | 347,597 | 438,421 |
Property, plant and equipment, net | 38,232 | 33,484 |
Operating lease right-of-use assets | 35,773 | 39,591 |
Other non-current assets | 1,809 | 2,003 |
Total assets | 423,411 | 513,499 |
Current liabilities: | ||
Accounts payable | 1,326 | 2,512 |
Accrued liabilities | 31,544 | 33,621 |
Lease liabilities | 5,834 | 5,816 |
Deferred revenue | 3,777 | 2,736 |
Total current liabilities | 42,481 | 44,685 |
Lease liabilities, non-current | 34,672 | 35,356 |
Deferred revenue, non-current | 143,024 | 146,195 |
Total liabilities | 220,177 | 226,236 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock, $0.01 par value; 200,000,000 shares authorized as of December 31, 2023 and 2022; no shares issued and outstanding | 0 | 0 |
Additional paid-in-capital | 1,023,739 | 862,359 |
Accumulated other comprehensive income (loss) | 151 | (701) |
Accumulated deficit | (821,242) | (574,826) |
Total stockholders’ equity | 203,234 | 287,263 |
Total liabilities and stockholders’ equity | 423,411 | 513,499 |
Common Stock Class Undefined | ||
Stockholders' equity: | ||
Common stock, value | 331 | 294 |
Non-voting Common Stock | ||
Stockholders' equity: | ||
Common stock, value | $ 255 | $ 137 |